Margaret Mcloughlin Biography and Net Worth

Director of Cortexyme


Dr. Margaret A. Mcloughlin Ph.D. serves as Independent Director of the Company. From January 2014 to April 2019, Dr. McLoughlin served as an Executive Director in World Wide Business Development, at Pfizer Inc. focusing on venture investments, and from June 2018 to April 2019, she was a Partner in Pfizer Ventures, a venture capital arm of Pfizer Inc. focused on companies working in areas aligned with the future directions of Pfizer Inc. Dr. McLoughlin served as a director on the board of directors of 4D Molecular Therapeutics, System1 Biosciences and Adapsyn Biosciences. Dr. McLoughlin joined Pfizer Inc. in 2001 and prior to focusing on venture investments, had roles of increasing responsibility within Worldwide Business Development where she led transactions with multiple biotech companies, academic institutions and other large pharma companies. Prior to working at Pfizer Inc., Dr. McLoughlin served as a Director in Yale’s Office of Cooperative Research for two years. Dr. McLoughlin served in various positions at Mallinckrodt Medical from 1992 to 1999, holding positions in Discovery Research, followed by Technology Planning. Dr. McLoughlin holds a B.S. in Chemistry from the University of California, Irvine and a Ph.D. in Chemistry from the University of California, Santa Barbara. McLoughlin is qualified to serve as a director because of her extensive experience in the biotechnology industry and her service on a number of boards, which provides an important perspective on operations and corporate governance matters, as well as her education in biotechnology.

What is Margaret Mcloughlin's net worth?

The estimated net worth of Margaret Mcloughlin is at least $16,640.00 as of August 8th, 2023. Dr. Mcloughlin owns 8,000 shares of Cortexyme stock worth more than $16,640 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Mcloughlin may own. Learn More about Margaret Mcloughlin's net worth.

How do I contact Margaret Mcloughlin?

The corporate mailing address for Dr. Mcloughlin and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Margaret Mcloughlin's contact information.

Has Margaret Mcloughlin been buying or selling shares of Cortexyme?

Margaret Mcloughlin has not been actively trading shares of Cortexyme during the past quarter. Most recently, Margaret Mcloughlin sold 1,000 shares of the business's stock in a transaction on Friday, October 8th. The shares were sold at an average price of $88.93, for a transaction totalling $88,930.00. Learn More on Margaret Mcloughlin's trading history.

Who are Cortexyme's active insiders?

Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Margaret Mcloughlin Insider Trading History at Cortexyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/8/2021Sell1,000$88.93$88,930.00View SEC Filing Icon  
8/16/2021Sell6,000$95.44$572,640.006,000View SEC Filing Icon  
6/28/2021Sell550$55.15$30,332.50350View SEC Filing Icon  
See Full Table

Margaret Mcloughlin Buying and Selling Activity at Cortexyme

This chart shows Margaret Mcloughlin's buying and selling at Cortexyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cortexyme Company Overview

Cortexyme logo
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.08
Low: $1.80
High: $2.14

50 Day Range

MA: $1.07
Low: $0.69
High: $1.95

2 Week Range

Now: $2.08
Low: $1.78
High: $40.66

Volume

312,412 shs

Average Volume

620,672 shs

Market Capitalization

$62.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4